

BUY TP: Rs 6,530 | A 20%

INFO EDGE

Internet

Naukri poised for accelerated growth; upgrade to BUY

- In-line Q1 with revenue up 14% YoY (deferred revenue up 36%) and EBITDA margin at 31.2%
- Tech talent crunch in IT/ITES verticals to catalyse growth for Naukri; favourable real estate market dynamics to aid 99acres
- Upgrade to BUY (vs. SELL) with a new Jun'22 TP of Rs 6,530 (vs. Rs 2,880) on better traction in Naukri and upcoming recovery of 99acres

Robust quarterly performance: In line with our estimate, INFOE reported 14% YoY revenue growth in Q1FY22, its first quarter of positive YoY growth since the onset of Covid-19. EBITDA margin stood at 31.2%, up 13ppt QoQ (down 610bps YoY). Billing recovered significantly, rising 67% YoY. Growth was led by a 74% YoY rise in Naukri billings. Deferred sales increased 36% YoY, the best print in 11 quarters, indicating better growth in the near future.

99acres saw Covid 2.0 impact but outlook positive: Since home buying is a high involvement category, it suffered heavily during the second Covid wave. Although 99acres' billing was up 60% YoY, it declined 69% QoQ. In tandem, INFOE curtailed 99acres' advertising spend in Q1 as Covid 2.0 led to a second lockdown. Management indicated that traffic has started to return from July onwards with the easing of restrictions. A favourable real estate industry dynamic (low interest rate, better affordability and Covid-linked willingness to buy bigger houses) sets an optimistic outlook for the business. Management indicated healthy traction on rentals as well.

Tech talent crunch brightens up Naukri outlook: Naukri's Q1 revenue increased 11.2% YoY on the back of 21% YoY growth in the IT/ITES vertical. Management also indicated buoyant hiring activity on the Naukri platform led by a technology talent crunch. The Jul'21 Jobspeak index for IT/ITES reached a record high, growing 200%+ YoY and confirming robust demand. INFOE expects strong traction led by (1) higher realisation (shaped by the absence of bulk discounts, otherwise a common practice), (2) increased volumes, and (3) expansion of client base.

Covid reshaped Naukri seasonality: Deferral of annual contract renewal amid Covid-19 has changed Naukri's seasonality. Management now expects better traction for the business in Q2 and Q3 led by the altered client contract renewal cycle.

Upgrade to BUY: We upgrade INFOE to BUY from SELL on the back of a revitalised revenue and margin outlook for Naukri.com. We raise our FY22/FY23 EPS by 11%/15% and roll to a Jun'22 SOTP-based TP of Rs 6,530 (vs. Rs 2,880).

17 August 2021

Ruchi Burde | Seema Nayak researchreport@bobcaps.in

Key changes

	Target	Rating	
	A	A	
Ticker	/Price	INFOE IN/Rs 5,446	
Marke	t cap	US\$ 9.4bn	
Free fl	oat	62%	
3M AD	V	US\$ 41.9mn	
52wk ł	nigh/low	Rs 5,880/Rs 3,220	
Promo	ter/FPI/DII	38%/38%/24%	

Source: NSE | Price as of 16 Aug 2021

Key financials


86 13,804 72 4,495	16,488 5,389
,	5,389
39 4,408	5,086
1.3 34.3	39.5
1.3 28.5	34.4
7.8 9.3	10.0
5.8 158.9	137.7
1.9 154.7	128.5
.7) 61.0	15.4
	1.3 34.3 1.3 28.5 7.8 9.3 5.8 158.9 1.9 154.7

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

Stock performance



Source: NSE







Other earnings call highlights

- JobHai.com, INFOE's blue collar hiring platform, is being tested in the Delhi-NCR market.
- Naukri's Gulf business has recovered only modestly as there are no IT sector tailwinds there.
- IIMJobs, INFOE's premium hiring platform, showed robust revenue growth (170% YoY) as well profitability in Q1FY22, although on a small base.
- Traffic on 99acres has started recovering from July onwards.
- INFOE will continue to spend heavily on Jeevansaathi's marketing, especially in the Hindi-speaking belt. Marketing spend for 99acres will depend on the real estate demand environment.

(Rs mn) Q1FY22 Q1FY21 YoY (%) Q4FY21 QoQ (%) FY21 FY20 YoY (%) Revenue 3,197 2,801 14.1 2,900 10.2 10,986 12,727 (13.7) **Operating Expenditure** 2,200 1,756 25.3 2371 (7.2) 8,214 8,700 (5.6) Cost of revenues 1,742 1,500 16.1 1,811 (3.9)252 234 7.8 2 2 24.8 as % of sales 54 54 -62 _ 256 79.3 560 2,044 SG&A expenses 459 (18.1) 1,820 (11.0)as % of sales 14 9 19 17 16 3.1 -_ EBITDA 997 1,046 (4.7) 529 88.4 2,772 4,027 (31.2) Depreciation 436 414 103 111 (7.3) 106 (2.4)5.5 EBIT 894 934 423 111.1 2,336 3,614 (35.4) (4.3) Other Income 410 203 102.1 406 0.8 1188 876 35.6 PBT 15.0 1,290 1,122 784 64.6 3,434 3,190 7.7 Total Tax 280 290 120 133.3 727.7 1133.2 (3.3) (35.8) Adjusted PAT 1,010 832 21.4 664 2,706 52.2 2,057 31.6 (Profit)/loss from JV's/Ass/MI -_ _ _ -_ -**Reported PAT** 1,010 832 21.4 664 52.2 2,706 2,057 31.6 Reported EPS 7.9 6.8 16.0 5.2 52.2 21.0 16.9 24.5 Margins (%) EBITDA 31.2 37.3 (610) 18.2 1,290 25.2 31.6 (640) EBIT 28.0 33.4 (540) 14.6 1,340 21.3 28.4 (710) EBT 40.4 40.0 27.0 1,330 31.3 25.1 620 30 PAT 31.6 29.7 190 22.9 870 24.6 16.2 850 21.7 37.1 640 Effective Tax rate (1,540)15.3 21.2 35.5 (1,430)

Source: BOBCAPS Research, Company

Fig 1 – Quarterly performance

_



Valuation methodology

We upgrade INFOE to BUY from SELL on a revitalised growth outlook for Naukri. Baking in higher revenue growth coupled with operating margin leverage at the jobs portal, we raise our FY22/FY23 EPS estimates by 11%/15%.

We use the SOTP method wherein we value (1) Naukri.com at 110.5x P/E (average one-year forward post Covid multiple of INFOE sans Zomato and PolicyBazaar valuation), and (2) 99acres/Jeevansaathi.com at 18x/12x sales (vs. 11x and 9x sales earlier). Zomato is valued at US\$ 14.3bn (per current valuation) and PolicyBazaar at US\$ 2.4bn (per latest funding round). Post rollover, we have a revised Jun'22 TP of Rs 6,530 (vs. Rs 2,880 earlier).

Fig 2 – Revised estimates

(Po mn)		New		Old		Change (%)
(Rs mn)	FY22E	FY23E	FY24E	FY22E	FY23E	FY22E	FY23E
Revenue	13,804	16,488	19,225	13,051	15,217	5.8	8.4
YoY growth (%)	25.6	19.4	16.6	18.8	16.6	-	-
EBITDA	4,495	5,389	6,216	3,902	4,466	15.2	20.7
EBITDA margin (%)	32.6	32.7	32.3	29.9	29.3	-	-
PAT	4,408	5,086	5,623	3,987	4,434	10.6	14.7
EPS (Rs)	34.2	39.5	43.7	31.0	34.4	10.6	14.7

Source: BOBCAPS Research

Fig 3 – Key assumptions	
-------------------------	--

J				
Parameter	FY21	FY22E	FY23E	FY24E
Naukri.com				
Revenue growth YoY (%)	(15.0)	20.8	20.8	17.6
EBITDA Margin (%)	56.2	59.0	59.0	57.5
99acres.com				
Revenue growth YoY (%)	(23.8)	18.8	18.8	16.6
EBITDA Margin (%)	(6)	(10)	(10)	(10)
Courses Company BOBCARC Research				

Source: Company, BOBCAPS Research

Fig 4 – Valuation summary

SOTP valuation	Method	Value (Rs mn)	% stake	Value of the stake (Rs mn)	Value (Rs/sh)	% of total value
Naukri.com	110.5x P/E	511,058	100	511,058	3,972	61
99acres	18x sales	44,142	100	44,142	343	5
Jeevansathi	12x sales	27,566	100	27,566	214	3
Zomato	Valued at US\$ 14.3bn – as per Aug'21 valuation	1,086,800	15	165,520	1,287	20
PolicyBazaar	Valued at US\$ 2.4bn – as implied by latest transaction	380,000	14	51,300	399	6
Other investments	Book value	5,059	na	5,059	39	1
Cash and Cash equivalent	Book value	35610	100	35,610	277	4

Source: BOBCAPS Research

Fig 5 – Peer comparison

Compony	Price	Price TP ^I (Rs/sh)	тр	тр	тр	тр	тр	тр	тр	тп	тр	Revenue CAGR	EPS CAGR	PE (x)		RoE (%)		
Company	(Rs/sh)		FY21-24E %	FY21-24E %	FY22	FY23	FY21	FY22	FY23									
Infoedge	5445.8	6,530	23	36	159	138	7.8	9.3	10.0									
IndiaMart	7180.2	7,200	21	17	65	54	30.3	19.0	19.3									
Affle India	4179.6	6,200	43	32	68	45	37.6	14.6	18.1									
Just Dial	958.3	1,330	11	3	79	29	16.8	4.2	7.5									

Source: BOBCAPS Research

Key risks

 A key downside risk to our estimates is the real estate sector taking longer to recover post Covid 2.0.

Sector recommendation snapshot

Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
AFFLE IN	1.5	4,180	6,200	BUY
INMART IN	2.9	7,170	7,200	HOLD
INFOE IN	9.4	5,446	6,530	BUY
JUST IN	0.8	958	1,330	BUY
	AFFLE IN INMART IN INFOE IN	AFFLE IN 1.5 INMART IN 2.9 INFOE IN 9.4	AFFLE IN 1.5 4,180 INMART IN 2.9 7,170 INFOE IN 9.4 5,446	AFFLE IN 1.5 4,180 6,200 INMART IN 2.9 7,170 7,200 INFOE IN 9.4 5,446 6,530

Source: BOBCAPS Research, NSE | Price as of 16 Aug 2021



Financials (Standalone)

Income Statement

income Statement					
Y/E 31 Mar (Rs mn)	FY20A	FY21P	FY22E	FY23E	FY24E
Total revenue	12,727	10,986	13,804	16,488	19,225
EBITDA	4,027	2,772	4,495	5,389	6,216
Depreciation	414	436	483	577	673
EBIT	3,614	2,336	4,011	4,811	5,543
Net interest inc./(exp.)	(67)	(57)	(72)	(86)	(100)
Other inc./(exp.)	876	1,188	1,951	2,071	2,071
Exceptional items	(1,233)	(32)	0	0	0
EBT	3,190	3,434	5,891	6,797	7,514
Income taxes	1,133	728	1,483	1,711	1,891
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	2,057	2,706	4,408	5,086	5,623
Adjustments	1,233	32	0	0	0
Adjusted net profit	3,290	2,739	4,408	5,086	5,623
rajuotou not pront	0,200	2,100	4,400	0,000	

Balance Sheet

Y/E 31 Mar (Rs mn)	FY20A	FY21P	FY22E	FY23E	FY24E
Accounts payables	592	601	756	903	1,053
Other current liabilities	4,890	5,501	6,242	7,455	8,692
Provisions	549	662	662	662	662
Debt funds	2	1	1	1	1
Other liabilities	761	652	652	652	652
Equity capital	1,223	1,285	1,285	1,285	1,285
Reserves & surplus	23,094	44,357	47,662	51,475	55,691
Shareholders' fund	24,317	45,642	48,947	52,761	56,976
Total liab. and equities	31,110	53,059	57,261	62,435	68,037
Cash and cash eq.	4,254	6,332	10,470	15,580	21,110
Accounts receivables	70	54	76	90	105
Inventories	0	0	0	0	0
Other current assets	8,722	23,545	23,545	23,545	23,545
Investments	14,672	15,000	15,000	15,000	15,000
Net fixed assets	434	318	360	409	467
CWIP	0	0	0	0	0
Intangible assets	41	37	37	37	37
Deferred tax assets, net	335	363	363	363	363
Other assets	2,582	7,410	7,410	7,410	7,410
Total assets	31,110	53,059	57,261	62,435	68,037

Cash Flows

Y/E 31 Mar (Rs mn)	FY20A	FY21P	FY22E	FY23E	FY24E
Cash flow from operations	3,256	2,828	5,695	6,924	7,568
Capital expenditures	(237)	(81)	(525)	(627)	(731)
Change in investments	907	2,560	0	0	0
Other investing cash flows	819	(21,981)	72	86	100
Cash flow from investing	1,489	(19,502)	(453)	(541)	(631)
Equities issued/Others	3	18,752	0	0	0
Debt raised/repaid	0	0	0	0	0
Interest expenses	(199)	0	0	0	0
Dividends paid	(978)	0	(1,103)	(1,273)	(1,407)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(1,174)	18,752	(1,103)	(1,273)	(1,407)
Chg in cash & cash eq.	3,571	2,077	4,138	5,110	5,530
Closing cash & cash eq.	4,253	6,332	10,470	15,580	21,110

Per Share Y/E 31 Mar (Rs)	FY20A	FY21P	FY22E	FY23E	FY24E
Reported EPS	16.0	21.0	34.3	39.5	43.7
Adjusted EPS	25.6	21.0	34.3	39.5	43.7
Dividend per share	6.0	0.0	8.6	9.9	43.7
Book value per share	189.0	354.8	380.4	410.1	442.9
Book value per silare	109.0	334.0	300.4	410.1	442.3
Valuations Ratios					
Y/E 31 Mar (x)	FY20A	FY21P	FY22E	FY23E	FY24E
EV/Sales	55.0	63.6	50.4	42.0	35.8
EV/EBITDA	173.8	251.9	154.7	128.5	110.6
Adjusted P/E	213.0	255.8	158.9	137.7	124.6
P/BV	28.8	15.4	14.3	13.3	12.3
DuPont Analysis					
Y/E 31 Mar (%)	FY20A	FY21P	FY22E	FY23E	FY24E
Tax burden (Net profit/PBT)	103.1	79.7	74.8	74.8	74.8
Interest burden (PBT/EBIT)	88.3	147.0	146.9	141.3	135.0
EBIT margin (EBIT/Revenue)	28.4	21.3	29.1	29.2	28.
Asset turnover (Rev./Avg TA)	42.1	26.1	25.0	27.6	29.
Leverage (Avg TA/Avg Equity)	1.3	1.2	1.2	1.2	1.1
Adjusted ROAE	13.8	7.8	9.3	10.0	10.2
Ratio Analysis					
Y/E 31 Mar	FY20A	FY21P	FY22E	FY23E	FY24E
YoY growth (%)					
Revenue	15.9	(13.7)	25.6	19.4	16.6
EBITDA	18.0	(31.2)	62.1	19.9	15.3
Adjusted EPS	4.4	(16.7)	61.0	15.4	10.5
Profitability & Return ratios (%)		(- 7			
EBITDA margin	31.6	25.2	32.6	32.7	32.3
EBIT margin	28.4	21.3	29.1	29.2	28.8
Adjusted profit margin	25.8	24.9	31.9	30.8	29.2
Adjusted ROAE	13.8	7.8	9.3	10.0	10.2
ROCE	8.3	7.5	9.1	9.7	10.0
Working capital days (days)					
Receivables	2	2	2	2	2
	0	0	0	0	(
Inventory	0				
Inventory Payables	17	20	18	18	19
,	-	20	18	18	19
Payables	-	20 29.2	18 40.7	18 42.9	19 43.9

Adjusted debt/equity (0.2) (0.1) Source: Company, BOBCAPS Research | Note: TA = Total Assets

Net interest coverage ratio

0.0

0.0

0.0

(0.2)

0.0

(0.3)

0.0

(0.4)



Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): INFO EDGE (INFOE IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Rating distribution

As of 31 July 2021, out of 98 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 41 have BUY ratings, 22 have HOLD ratings, 11 are rated ADD*, 2 are rated REDUCE* and 22 are rated SELL. None of these companies have been investment banking clients in the last 12 months. (*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

INFO EDGE



This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.